FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors

ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase 1 study to evaluate the safety and preliminary efficacy of its m-ceNK platform in subjects with locally advanced or metastatic solid tumors.

The cell therapy product will be manufactured thanks to a novel method, which yields multiple clinical-doses from a single apheresis using the company’s proprietary NANT 001 Bioreactor, developed and supplied by VivaBioCell.

Read ImmunityBio Press Release: FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors.